4.5 Article

Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients

Journal

VACCINE
Volume 29, Issue 34, Pages 5638-5644

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.06.013

Keywords

HIV; A/H1N1; Pandemic influenza; Vaccine coverage

Funding

  1. BioCryst
  2. Biomerieux
  3. BMS
  4. GSK
  5. Merck
  6. Novartis
  7. Roche
  8. Sanofi-Pasteur

Ask authors/readers for more resources

Background: A mass influenza A/H1N1 vaccination campaign took place in France during the 2009 winter. Overall, 7.9% of the general population was vaccinated. However, vaccine coverage data are missing for at-risk groups. Methods: A vaccination centre was implemented for HIV-infected patients followed-up in a French University Hospital. Demographical, clinical and biological characteristics were collected. Adjusted odds ratios (aOR) were calculated to identify factors associated with being vaccinated against A/H1N1 influenza. Results: A/H1N1 vaccine coverage was 44.4% (635/1430) in HIV-infected patients. In univariate analysis, uptake of vaccination was significantly associated with male gender, men who have sex with men, age >= 50 years, >= 1 seasonal influenza risk factor, longer HIV disease, longer duration of antiretroviral therapy, greater number of lines of antiretroviral treatments, lower nadir CD4, recent HIV-RNA <50 copies/ml, previous pneumococcal vaccination, >2 visits to the unit during the study period and follow-up by a physician who assessed >= 100 patients/year (senior physician). CDC stage, recent CD4 count, diabetes, BMI > 30 and pregnancy were not associated with vaccination. After multivariate analysis, vaccination remained significantly associated with age >= 50 years (aOR 1.56, CI 1.16-2.09), time since HIV diagnosis (aOR per 1 year 1.02, CI 1.00-1.04), previous pneumococcal vaccination (aOR 2.56, CI 1.96-3.34), >2 visits to the unit (aOR 5.09, CI 3.87-6.68) and follow-up by a senior physician (aOR 1.73, CI 1.20-2.48). Conclusion: A/H1N1 vaccination was more successful in HIV-infected patients than in the French general population. Organization of the vaccination in a convenient location and implication of the physicians seem to be determining factors for A/H1N1 acceptability in this population. (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available